All In Biotech

Drug Trial Radar · NCT04766307

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

A Randomized Multicenter Clinical Trial of a New Treatment for Primary Smear- Positive Pulmonary Tuberculosis With Interleukin-2

Last checked: Nov 19, 2026Latest source record: Feb 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 1,100 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,100

Planned (sponsor's estimate)

Start

Jul 20, 2016

Primary completion

Dec 31, 2021

Study completion Dec 31, 2021

Sponsor

Lead sponsor
Beijing Chest HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 23, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.

Conditions

  • Tuberculosis, Pulmonary

Interventions

  • Interleukin-2Drug

    Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment.Time frame: two-month course intensive phase treatment, followed by a four-month consolidation phase treatment.Some TB patients with cavity should receive 9 total months (7 months of continuation therapy after the initial 2-month intensive phase).

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • the Second hospital of Fuyang

    Fuyang, Anhui, China · Recruiting

  • Fuzhou Chest Hospital

    Fuzhou, Fujian, China · Recruiting

  • Shenzhen third people's Hospital

    Shenzhen, Guangzhou, China · Recruiting

  • Guiyang Public Health Treatment Center

    Guiyang, Guizhou, China · Recruiting

  • The Infectious Hospital of Handan

    Handan, Hebei, China · Recruiting

  • Hebei Chest Hospital

    Shijiazhuang, Hebei, China · Recruiting

  • Jiamusi Insititute For Tuberculosis Control

    Jiamusi, Heilongjiang, China · Recruiting

  • The Infectious Hospital of mudanjiang

    Mudanjiang, Heilongjiang, China · Recruiting

  • Zhengzhou Sixth People's Hospital

    Zhengzhou, Henan, China · Recruiting

  • the central hospital of Changsha

    Changsha, Hunan, China · Recruiting

  • the people's hospital of Jiangsu province

    Nanjing, Jiangsu, China · Recruiting

  • Jiangxi Chest Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Dalian Tuberculosis Hospital

    Dalian, Liaoning, China · Recruiting

  • Qingdao Chest Hospital

    Qingdao, Shandong, China · Recruiting

  • Taiyuan Fourth People's Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Xian Chest Hospital

    Xi’an, Shanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.